• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance.现在应实施含青蒿素三联疗法以延缓耐药性的出现。
Malar J. 2019 Oct 11;18(1):338. doi: 10.1186/s12936-019-2955-z.
2
Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance: the case against.现应实施含三种青蒿素的联合抗疟治疗以延缓耐药性产生：反对意见。
Malar J. 2019 Oct 3;18(1):339. doi: 10.1186/s12936-019-2976-7.
3
Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.三药联合疗法与青蒿素类复方疗法治疗无并发症恶性疟原虫疟疾的比较：一项多中心、开放标签、随机临床试验。
Lancet. 2020 Apr 25;395(10233):1345-1360. doi: 10.1016/S0140-6736(20)30552-3. Epub 2020 Mar 11.
4
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria.在布基纳法索和尼日利亚部署三药联合疗法治疗疟疾的伦理考虑：利益攸关方观点分析。
PLoS One. 2022 Sep 9;17(9):e0273249. doi: 10.1371/journal.pone.0273249. eCollection 2022.
5
[Combined antimalarial therapy using artemisinin].[使用青蒿素的联合抗疟疗法]
Parassitologia. 2004 Jun;46(1-2):85-7.
6
Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?三药联合疗法治疗疟疾——一种新模式？
Trends Parasitol. 2021 Jan;37(1):15-24. doi: 10.1016/j.pt.2020.09.011. Epub 2020 Oct 12.
7
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.寄生虫过度感染和低剂量用药是抗疟药物产生抗药性的一个重要原因。
Malar J. 2009 Nov 11;8:253. doi: 10.1186/1475-2875-8-253.
8
Malaria and artemisinin derivatives: an updated review.疟疾和青蒿素衍生物：最新综述。
Mini Rev Med Chem. 2013 Nov;13(13):1879-902. doi: 10.2174/13895575113136660097.
9
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?在多大程度上，非洲国家的抗疟市场为向三药复方疗法过渡做好了准备？
PLoS One. 2021 Aug 31;16(8):e0256567. doi: 10.1371/journal.pone.0256567. eCollection 2021.
10
Access to artemisinin-based combination therapies and other anti-malarial drugs in Kinshasa.金沙萨青蒿素类复方疗法和其他抗疟药物的获取途径。
Med Mal Infect. 2018 Jun;48(4):269-277. doi: 10.1016/j.medmal.2018.02.003. Epub 2018 Mar 9.

引用本文的文献

1
YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates.YAT2150对恶性疟原虫具有不可阻挡的作用，并且对间日疟原虫和利什曼原虫临床分离株具有活性。
Sci Rep. 2025 Jan 23;15(1):2941. doi: 10.1038/s41598-025-85346-y.
2
Emerging trends and new developments in global research on artemisinin and its derivatives.青蒿素及其衍生物全球研究的新趋势与新进展
Heliyon. 2024 Dec 9;11(1):e41086. doi: 10.1016/j.heliyon.2024.e41086. eCollection 2025 Jan 15.
3
Artemisinin-resistant malaria.抗青蒿素疟疾
Clin Microbiol Rev. 2024 Dec 10;37(4):e0010924. doi: 10.1128/cmr.00109-24. Epub 2024 Oct 15.
4
Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar.分子标志物在缅甸东部消除恶性疟原虫疟疾中的应用。
Malar J. 2024 May 8;23(1):138. doi: 10.1186/s12936-024-04955-6.
5
Strategies for deploying triple artemisinin-based combination therapy in the Greater Mekong Subregion.大湄公河次区域部署三药联合疗法的策略。
Malar J. 2023 Sep 6;22(1):261. doi: 10.1186/s12936-023-04666-4.
6
Pharmacopeial quality of artemether-lumefantrine anti-malarial agents in Uganda.乌干达青蒿琥酯-咯萘啶抗疟药的药典质量。
Malar J. 2023 May 26;22(1):165. doi: 10.1186/s12936-023-04600-8.
7
Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya.在肯尼亚西部 Asembo，人类血液中疟原虫耐药分子标志物的时间趋势及蚊卵中相应耐药标志物的特征。
Malar J. 2022 Sep 13;21(1):265. doi: 10.1186/s12936-022-04284-6.
8
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria.在布基纳法索和尼日利亚部署三药联合疗法治疗疟疾的伦理考虑：利益攸关方观点分析。
PLoS One. 2022 Sep 9;17(9):e0273249. doi: 10.1371/journal.pone.0273249. eCollection 2022.
9
Expert perspectives on the introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi study.专家视角下的东南亚引入三药联合疗法（TACTs）：德尔菲研究。
BMC Public Health. 2022 Apr 30;22(1):864. doi: 10.1186/s12889-022-13212-x.
10
Market Formation in a Global Health Transition.全球卫生转型中的市场形成
Environ Innov Soc Transit. 2021 Sep;40:40-59. doi: 10.1016/j.eist.2021.05.003.

本文引用的文献

1
Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.中医疗法治疗失败的决定因素：柬埔寨、泰国和越南间日疟原虫疟疾的前瞻性临床、药理学和遗传学研究。
Lancet Infect Dis. 2019 Sep;19(9):952-961. doi: 10.1016/S1473-3099(19)30391-3. Epub 2019 Jul 22.
2
WHO, the Global Fund, and medical malpractice in malaria treatment.世界卫生组织、全球基金与疟疾治疗中的医疗事故
Lancet. 2004 Jan 17;363(9404):237-40. doi: 10.1016/S0140-6736(03)15330-5.
3
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.体内抗疟药物药效学特性评估。
Antimicrob Agents Chemother. 1997 Jul;41(7):1413-22. doi: 10.1128/AAC.41.7.1413.

现在应实施含青蒿素三联疗法以延缓耐药性的出现。

Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance.

机构信息

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand.

出版信息

Malar J. 2019 Oct 11;18(1):338. doi: 10.1186/s12936-019-2955-z.

DOI:10.1186/s12936-019-2955-z
PMID:31581941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6777025/
Abstract

Resistance threatens all our currently available anti-malarial drugs. Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs. TACTs are undergoing large-scale trials. If they prove safe, well-tolerated and efficacious then they should be deployed. This is in order to protect and extend the useful therapeutic life of the current generation of anti-malarial drugs, which are so essential for malaria control and elimination.

摘要

耐药性威胁到我们现有的所有抗疟药物。三药复方青蒿素抗疟疗法（TACT）将青蒿素衍生物与两种消除缓慢的联合药物相结合。TACT 正在进行大规模试验。如果它们被证明是安全的、耐受良好且有效的，那么就应该部署它们。这是为了保护和延长当前一代抗疟药物的有效治疗寿命，这些药物对于疟疾控制和消除至关重要。